DIA2 Antibody

What is DIA2 and why is it important in cellular research?

DIA2 (Diaphanous-related formin 2) is a protein encoded by the DIAPH2 gene and serves as a critical regulator of actin dynamics within cells. It belongs to the formin homology protein family and is essential for the formation and elongation of actin filaments . The importance of DIA2 in research stems from its fundamental roles in maintaining cell shape, facilitating cell motility, and ensuring proper cell division through cytoskeletal organization . Additionally, DIA2 has specialized functions in reproductive biology, with significant expression in testis and ovary tissues where it influences oogenesis . Mutations in the DIAPH2 gene have been linked to premature ovarian failure type 2A, making it a relevant target for reproductive health research . Understanding DIA2 function provides crucial insights into cytoskeletal regulation mechanisms and reproductive development pathways.

What are the structural characteristics of human DIA2 protein?

Human DIA2 (DIAPH2) has a canonical amino acid length of 1101 residues and a molecular mass of approximately 125.6 kilodaltons . The protein exists in three alternatively spliced isoforms, which may contribute to diverse functional roles in different cellular contexts . As a member of the formin family, DIA2 contains conserved formin homology domains that are critical for its actin-regulatory functions. The protein is primarily localized in the cytoplasm of cells, where it interacts with actin and other cytoskeletal regulatory proteins . These structural characteristics enable DIA2 to function as a nucleation factor for linear actin filaments, contributing to cytoskeletal organization and dynamics across various cellular processes.

How is DIA2 expression distributed across different tissue types?

DIA2 (DIAPH2) is widely expressed across many tissue types in the human body, reflecting its fundamental role in cellular architecture and function . While it has broad tissue distribution, research has shown particularly notable expression in reproductive tissues, especially the testis and ovary . This tissue-specific enrichment aligns with DIA2's established role in oogenesis and the observed clinical correlation between DIAPH2 mutations and premature ovarian failure . When designing experiments to study DIA2, researchers should consider this differential expression pattern, which may influence the selection of appropriate cell lines and tissue models. Understanding the tissue distribution profile helps in contextualizing experimental findings and determining the physiological relevance of observed effects in specific biological systems.

How do different DIA2 isoforms affect experimental outcomes in actin dynamics studies?

The existence of three alternatively spliced isoforms of DIA2 introduces significant complexity to actin dynamics investigations . Each isoform may exhibit differential binding affinities to actin monomers, varied rates of nucleation activity, and distinct interactions with regulatory proteins. When designing experiments to study actin assembly, researchers should consider which specific isoform(s) are expressed in their model system. Methodologically, this requires:

• Preliminary Western blot analysis using isoform-discriminating antibodies to determine which variants are present in your experimental system

• Using recombinant expression systems with isoform-specific constructs for controlled comparative studies

• Implementing siRNA strategies targeting specific exons to selectively knockdown individual isoforms

• Employing super-resolution microscopy techniques to visualize potential isoform-specific spatial distributions at actin assembly sites

Research has shown that differential expression of these isoforms can significantly impact experimental outcomes, particularly in assays measuring actin polymerization rates, stress fiber formation, and cellular migration speeds . Failure to account for isoform variation represents a common source of inter-laboratory result discrepancies in DIA2 functional studies.

What mechanisms govern the interaction between DIA2 and other cytoskeletal regulatory proteins?

DIA2 functions within a complex network of cytoskeletal regulatory proteins, where its activity is precisely controlled through multiple protein-protein interactions . The primary regulatory mechanisms include:

To study these interactions effectively, researchers should employ multiple complementary approaches:

• In vitro reconstitution systems using purified components to establish direct interactions

• Proximity ligation assays to confirm interactions in cellular contexts

• Domain-specific mutations to map interaction interfaces

• Quantitative binding assays (ITC, SPR) to determine binding constants and kinetics

Understanding these regulatory interactions is crucial for interpreting phenotypes observed in DIA2 manipulation experiments and for developing targeted approaches to modulate specific DIA2 functions in research contexts .

What is the relationship between DIA2 mutations and premature ovarian failure type 2A?

The link between DIA2 (DIAPH2) mutations and premature ovarian failure type 2A represents a significant translational aspect of DIA2 research . Current evidence suggests multiple pathogenic mechanisms:

• Disruption of oocyte cytoskeletal architecture during early development

• Impaired spindle formation leading to increased chromosomal segregation errors

• Altered ovarian follicular cell migration and organization

• Compromised intercellular communication within the developing follicle

When investigating this relationship, researchers should employ:

• Patient-derived cell models (including iPSCs differentiated toward ovarian lineages)

• CRISPR-engineered animal models harboring specific patient mutations

• High-resolution imaging of oocyte cytoskeletal structures in model systems

• Transcriptomic analysis to identify dysregulated pathways downstream of mutant DIA2

The most informative experimental approach involves parallel analysis of multiple mutation variants to establish genotype-phenotype correlations. This requires careful antibody selection to ensure detection of mutant forms, potentially including custom antibody development for specific mutations of interest . Understanding this relationship provides valuable insights into both the molecular functions of DIA2 and the pathophysiology of premature ovarian failure.

What are the critical factors in selecting the appropriate DIA2 antibody for specific experimental applications?

Selecting the optimal DIA2 antibody requires careful consideration of several experimental parameters:

When selecting a DIA2 antibody, researchers should consider:

• Target epitope location relative to functional domains and splice junctions

• Cross-reactivity with related formin family members (particularly DIAPH1 and DIAPH3)

• Species reactivity relevant to experimental model (human, mouse, rat)

• Conjugation requirements for specialized applications (IF, flow cytometry)

What are the optimal protocols for immunoprecipitation of DIA2 and its interacting partners?

Effective immunoprecipitation of DIA2 requires specialized protocols to preserve protein-protein interactions while maintaining specificity:

• Lysis Buffer Optimization:

  • Standard recommendation: 50mM Tris-HCl (pH 7.4), 150mM NaCl, 1% NP-40, 0.25% sodium deoxycholate

  • Critical addition: Actin stabilizing components (1mM ATP, 1mM DTT, 5mM MgCl₂)

  • Protease/phosphatase inhibitors: Complete cocktail plus specific inhibitors for actin-regulatory pathway kinases

• Antibody Selection and Conjugation:

  • Preferred antibody: Mouse monoclonal anti-DIA2 (C-12)

  • Protein A/G magnetic beads provide superior recovery compared to agarose

  • Cross-linking antibody to beads (using BS3) reduces heavy chain interference in subsequent analysis

• Experimental Workflow:

  • Pre-clearing lysate: 1 hour with naked beads at 4°C

  • Antibody binding: 3-4 hours at 4°C under gentle rotation

  • Washing: 5-6 washes with decreasing salt concentration

  • Elution: Gentle acidic elution preserves interactions better than boiling in SDS

• Validation Controls:

  • Input control (5-10% of starting material)

  • IgG-matched isotype control

  • Competitive blocking with immunizing peptide

  • Reciprocal IP with antibodies against known interacting partners

This optimized protocol significantly enhances the detection of transient or weak interactions between DIA2 and other cytoskeletal regulatory proteins, providing more comprehensive insights into DIA2's functional network.

What are the key considerations for immunohistochemical detection of DIA2 in tissue samples?

Successful immunohistochemical (IHC) detection of DIA2 in tissue samples requires addressing several technical challenges:

• Fixation and Antigen Retrieval:

  • Preferred fixative: 4% paraformaldehyde (10-12 hours)

  • Critical step: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

  • Extended retrieval time (25-30 minutes) improves detection in reproductive tissues

• Antibody Selection and Validation:

  • Monoclonal antibodies (such as C-12) typically provide more consistent results

  • Working dilution: 1:100-1:200 range after optimization

  • Essential controls: Peptide competition assay and DIA2-knockdown tissues

• Signal Amplification Systems:

  • Tyramide signal amplification recommended for low-abundance tissues

  • Polymer-based detection systems reduce background in reproductive tissues

  • Automated platforms provide more consistent results than manual protocols

• Tissue-Specific Considerations:

  • Ovarian tissue: Special attention to prevent edge artifacts

  • Testicular tissue: Extended blocking (2 hours) reduces non-specific binding

  • Embryonic tissues: Reduced antibody concentration (1:300-1:400)

• Interpretation Guidelines:

  • Expected pattern: Predominantly cytoplasmic with occasional cortical enrichment

  • Quantification approach: H-score incorporating intensity and percentage positive cells

  • Validation: Correlation with mRNA expression by in situ hybridization

By addressing these methodological considerations, researchers can achieve reliable and reproducible DIA2 detection in diverse tissue samples, facilitating accurate interpretation of expression patterns in normal and pathological contexts.

How can researchers address non-specific binding issues when using DIA2 antibodies?

Non-specific binding represents a common challenge when working with DIA2 antibodies, particularly in complex tissue samples. A systematic troubleshooting approach includes:

• Buffer Optimization:

  • Increase blocking agent concentration (5% BSA or 5% normal serum)

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

  • Include 10mM glycine to block residual aldehyde groups from fixation

• Antibody-Specific Approaches:

  • Titrate antibody concentration using a gradient of dilutions

  • Pre-absorb antibody with acetone powder from negative control tissues

  • Consider custom affinity purification against the immunizing peptide

• Sample Preparation Refinements:

  • Extend blocking time to 2-3 hours at room temperature

  • Double the number of wash steps between antibody incubations

  • Implement dual blocking with both protein and non-protein blockers (BSA + 0.1% gelatin)

• Validation Controls:

  • Run parallel samples with isotype-matched control antibodies

  • Perform peptide competition assays with the immunizing peptide

  • Include tissues from knockout models or siRNA-treated samples

• Post-hoc Analysis:

  • Apply fluorescence intensity ratio measurements (target vs. background)

  • Implement computational background subtraction techniques

  • Use spectral unmixing for autofluorescent samples

By systematically addressing each potential source of non-specific binding, researchers can significantly improve signal-to-noise ratios and generate more reliable data when working with DIA2 antibodies across various experimental platforms.

What are the best practices for quantifying DIA2 protein levels in comparative studies?

Accurate quantification of DIA2 protein levels is essential for comparative studies across experimental conditions or disease states. Recommended best practices include:

• Western Blot Quantification:

  • Loading controls: Prefer GAPDH over β-actin (given DIA2's role in actin regulation)

  • Technical replication: Minimum of 3 independent blots

  • Band selection: Verify correct molecular weight (125.6 kDa for canonical form)

  • Software: Use ImageJ with rolling ball background subtraction

  • Normalization: Report DIA2/loading control ratio with statistical analysis

• Immunofluorescence Quantification:

  • Image acquisition: Standardized exposure settings below saturation

  • Sampling: Minimum 50-100 cells per condition across 5-10 fields

  • Analysis: Mean fluorescence intensity with subcellular compartment masking

  • Controls: Include calibration samples in each imaging session

  • Statistics: Non-parametric tests due to typical non-normal distribution

• Flow Cytometry Approaches:

  • Fixation: 2% paraformaldehyde with gentle permeabilization

  • Controls: FMO (Fluorescence Minus One) controls essential

  • Gating: Hierarchical strategy with strict morphological criteria

  • Metrics: Report median fluorescence intensity rather than mean

  • Visualization: Superimposed histograms for condition comparison

• Considerations for Isoform Analysis:

  • When possible, use isoform-specific antibodies for separate quantification

  • RT-qPCR validation in parallel to confirm protein findings

  • Note differential detection efficiency across isoforms in methods section

How can researchers differentiate between specific DIA2 isoforms in experimental systems?

Differentiating between the three known DIA2 isoforms presents a significant technical challenge that requires specialized approaches:

• Antibody-Based Discrimination:

  • Epitope mapping: Select antibodies targeting isoform-specific regions

  • Western blotting: Utilize high-resolution SDS-PAGE (6% gels) for size-based separation

  • Validation: Recombinant isoform standards as positive controls

  • Limitation: Many commercial antibodies recognize multiple isoforms

• Molecular Biology Approaches:

  • RT-PCR: Design primers spanning alternative splice junctions

  • qPCR: Isoform-specific probe sets with normalized standard curves

  • Expression constructs: Tagged isoform-specific variants for controlled studies

  • RNA-seq: Specialized splice-junction analysis of sequencing data

• Proteomic Strategies:

  • Mass spectrometry: Focus on identifying isoform-specific peptides

  • Sample preparation: Immunoprecipitation enrichment before analysis

  • Data analysis: Specialized software for isoform discrimination

  • Limitation: Requires advanced instrumentation and expertise

• Functional Discrimination:

  • Domain-specific interaction assays

  • Subcellular localization patterns

  • Differential response to regulatory stimuli

  • Isoform-selective inhibitor sensitivity profiles

A comprehensive approach combining these methods provides the most reliable differentiation between DIA2 isoforms. Researchers should explicitly state which isoform(s) are being studied in their experimental system, as functional differences between isoforms can significantly impact interpretation of results and inter-study comparisons.

What emerging technologies are advancing DIA2 antibody-based research?

Recent technological developments are significantly enhancing DIA2 antibody-based research capabilities:

• Advanced Imaging Technologies:

  • Super-resolution microscopy (STORM, PALM) enabling visualization of DIA2 at actin nucleation sites

  • Lattice light-sheet microscopy for long-term live imaging of DIA2 dynamics

  • Expansion microscopy providing enhanced spatial resolution of cytoskeletal structures

  • Correlative light-electron microscopy linking DIA2 localization to ultrastructural features

• Innovative Antibody Formats:

  • Single-domain nanobodies against DIA2 for reduced steric hindrance

  • Bispecific antibodies targeting DIA2 and interacting partners simultaneously

  • Intrabodies expressed in specific subcellular compartments

  • Optogenetic antibody systems allowing light-controlled DIA2 inhibition

• Multiplexed Detection Systems:

  • Cyclic immunofluorescence for simultaneous detection of multiple cytoskeletal components

  • Mass cytometry (CyTOF) for high-dimensional protein expression analysis

  • Digital spatial profiling combining DIA2 detection with spatial transcriptomics

  • Quantum dot-conjugated antibodies for prolonged imaging and multiplexing

• Computational Approaches:

  • Machine learning algorithms for automated detection of DIA2-associated structures

  • Systems biology modeling of DIA2 interaction networks

  • Image analysis pipelines for quantifying dynamic DIA2 behaviors

  • Virtual screening platforms for identifying DIA2 modulating compounds

These emerging technologies are collectively advancing our ability to investigate DIA2 with unprecedented precision and contextual understanding, opening new avenues for research into this critical cytoskeletal regulator and its role in health and disease.

What are the current limitations in DIA2 antibody research, and how might they be addressed in future studies?

Current DIA2 antibody research faces several significant limitations that require innovative solutions:

• Isoform Discrimination Challenges:

  • Current limitation: Most antibodies detect multiple DIA2 isoforms simultaneously

  • Future direction: Development of highly isoform-specific antibodies using unique epitope targeting

  • Methodology advancement: Combining antibody detection with isoform-specific molecular probes

  • Complementary approach: CRISPR-based tagging of endogenous isoforms for unambiguous identification

• Temporal Resolution Constraints:

  • Current limitation: Standard immunodetection provides only static snapshots of dynamic processes

  • Future direction: Development of split-fluorescent protein systems for real-time DIA2 interaction monitoring

  • Methodology advancement: Engineered antibody fragments compatible with live-cell imaging

  • Complementary approach: Correlation of fixed-timepoint antibody data with live-imaging of labeled actin

• Quantification Standardization Issues:

  • Current limitation: Inconsistent quantification methodologies across studies

  • Future direction: Development of absolute quantification standards for DIA2 protein

  • Methodology advancement: Community-established reporting guidelines for DIA2 studies

  • Complementary approach: Creation of open-access image analysis pipelines specifically optimized for DIA2

• Functional Correlation Gaps:

  • Current limitation: Difficulty connecting antibody-detected localization to specific functions

  • Future direction: Development of conformation-specific antibodies detecting active vs. inactive DIA2

  • Methodology advancement: Integration of proximity labeling approaches with antibody detection

  • Complementary approach: Correlation of antibody binding with real-time force measurements